CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

NCT05054257 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma Refractory
Non-Hodgkin's Lymphoma, Relapsed

Interventions

DRUG: Autologous CAR19 T lymphocytes

Sponsor

Institute of Hematology and Blood Transfusion, Czech Republic